Amgen (NASDAQ:AMGN) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 4 | 4 | 1 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 1 | 0 |
| 2M Ago | 1 | 1 | 1 | 0 | 0 |
| 3M Ago | 1 | 2 | 3 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $341.18, a high estimate of $405.00, and a low estimate of $256.00. A decline of 3.38% from the prior average price target is evident in the current average.
Decoding Analyst Ratings: A Detailed Look
In examining recent analyst actions, we gain insights into how financial experts perceive Amgen. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Christopher Raymond | Piper Sandler | Lowers | Overweight | $310.00 | $344.00 |
| Tim Anderson | B of A Securities | Announces | Underperform | $256.00 | - |
| Gregory Renza | RBC Capital | Lowers | Outperform | $330.00 | $360.00 |
| Geoff Meacham | Citigroup | Announces | Neutral | $335.00 | - |
| Michael Yee | Jefferies | Maintains | Buy | $380.00 | $380.00 |
| Colin Bristow | UBS | Lowers | Neutral | $326.00 | $335.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Overweight | $405.00 | $405.00 |
| Yaron Weber | TD Cowen | Raises | Buy | $383.00 | $381.00 |
| Aaron Gal | Bernstein | Announces | Outperform | $380.00 | - |
| Robyn Karnauskas | Truist Securities | Raises | Hold | $333.00 | $320.00 |
| Carter Gould | Barclays | Raises | Equal-Weight | $315.00 | $300.00 |
Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Amgen. This information provides a snapshot of how analysts perceive the current state of the company. Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Amgen compared to the broader market. Price Targets: Delving into movements, analysts provide estimates for the future value of Amgen's stock. This analysis reveals shifts in analysts' expectations over time.
To gain a panoramic view of Amgen's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Amgen analyst ratings.
Discovering Amgen: A Closer Look
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Key Indicators: Amgen's Financial Health
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Amgen's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 23.18%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Amgen's net margin is impressive, surpassing industry averages. With a net margin of 33.28%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Amgen's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 42.08% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Amgen's ROA excels beyond industry benchmarks, reaching 3.11%. This signifies efficient management of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 8.02, Amgen faces challenges in effectively managing its debt levels, indicating potential financial strain.
Analyst Ratings: What Are They?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Latest Ratings for AMGN
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | Morgan Stanley | Maintains | Equal-Weight | |
| Feb 2022 | Wells Fargo | Maintains | Equal-Weight | |
| Feb 2022 | Barclays | Maintains | Equal-Weight |
View More Analyst Ratings for AMGN
View the Latest Analyst Ratings
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
